Fri, Apr 25, 2014, 1:11 AM EDT - U.S. Markets open in 8 hrs 19 mins


% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • frankposting frankposting Jul 21, 2013 4:43 PM Flag

    Why Anchor Is Huge

    Lovaza's off-label usage is about 70% of its sales. If Anchor gained approval, insurance should switch most of those off-label users to Anchor (Vascepa).

    Anchor: AdCom Oct 16; PDUFA Dec 20. In accordance with FDA's review on Vascepa, the approval of Anchor has no hurdles at all.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Frank: I am curious as to how you found this Lovaza off-label usage. Is there a publication or website that keep tracks of these sales?
      What do you think about Niaspan? Is it also in the same trig space with Lovaza and Vascepa and should be impacted by Vascepa's ANCHOR decision as well?

    • One thing to worry is doctors will not prescribe until there is proven cv outcomes benefit.
      We will need to wait for reduceit conclusions before real prescriptions would start. I tell you, if reduceit can demonstrate actual health benefit to lowering triglycerides, epa will be selling like mad.

    • "Lovaza's off-label usage is about 70% of its sales....."
      I've heard about it many times... sincerely I've never seen official link to it. Just for saying.
      That wpuld be very positive if confirmed.

      Wait and see

    • Frank
      I was always wondering where this number (70%) is coming from. Did you read this somewhere?

      Sentiment: Buy

    • AK

      "Getting rich overnight" is not realistic. Anchor may carry the PPS to a higher level. But the build-up of its full value may need three or four years from now (except a BO). And risks still be there. However, Anchor in October is a very significant milestone to AMRN. I doubled my position last week, may trade some in October, and hold the rest passing thro Reduce-It.

    • Frank
      Good pts
      So Lovaza is around 90k a week in scrips about 60K of that should go to Vascepa if you are correct.....and the time frame for that to happen ..6 months into 2014 ?...and based on Insurance challenging the MD's that currently prescribe Lovaza off label.
      I just think that unfortunately it all happens a lot slower then most think ...and don't mind if I'm wrong and discover its happening a lot faster then expected.

1.65+0.03(+1.85%)Apr 24 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million. Inc.
NasdaqGSThu, Apr 24, 2014 4:00 PM EDT
GW Pharmaceuticals plc
NasdaqGMThu, Apr 24, 2014 4:00 PM EDT